Memgen, LLC Report issue

For profit Phase 1 Phase 2
Founded: Houston TX United States (2004)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2006
NCT00850057
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Memgen, Inc.

Active Ingredients

Drugs in Phase 2 Trials (3)

isf35 (5 trials)

pembrolizumab (keytruda) (1 trial)

rad.cd40l (1 trial)

Drugs in Phase 1 Trials (2)

ad-isf35 (1 trial)

mem-288 intratumoral injection (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Melanoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial APIs: 5